A Phase 3 interventional study of Olokizumab and Placebo in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 116 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 368 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under R-Pharm International, LLC, one of the names counted as R-Pharm. Under that name alone:
R-Pharm International, LLC is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
R-Pharm has 5 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor
The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.
The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ in subjects with moderately to severely active RA who had responded inadequately to TNFi therapy. The primary endpoint of the trial was assessed at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period.
This was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety FollowUp Period from Week 24 to Week 44.
A total of 350 subjects were planned to be randomized.Subjects were assessed for eligibility to enter the study during a 4-week Screening Period. Eligible subjects were randomized at Visit 2 in a 2:2:1 ratio in one of 3 treatment groups (planned 140, 140, and 70 subjects per group, respectively) :
Subjects who received placebo were re-randomized at Week 16 to receive 64 mg OKZ q4w + Methotrexate or 64 mg OKZ q2w +Methotrexate for 8 weeks.
Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX with a stable route of administration. Concomitant treatment with folic acid was required for all subjects. The last dose of OKZ was administered at Week 20 for subjects receiving OKZ 64 mg q4w and at Week 22 for subjects receiving OKZ 64 mg q2w.
Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every 2 weeks through Week 24 for response and safety assessments.
At Week 14, subjects who did not improve by at least 20% in both swollen and tender joint counts were classified as nonresponders and were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment.
After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment.
Subjects who discontinued randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continue with the scheduled study visits.
Adverse events (AEs) were assessed throughout the study (starting when the subject signed the informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study by an independent Data Safety Monitoring Board and potential major adverse cardiac events were evaluated by an independent Cardiovascular Adjudication Committee.
The study was conducted at 123 sites across 11 countries globally (in US,EU, Russian Federation, Asia, Latin America)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects may be enrolled in the study only if they meet all of the following criteria.
(If the subject was diagnosed according to ACR 1987 criteria previously, the Investigator may classify the subject per ACR 2010 retrospectively, using available source data.)
Treatment with oral, SC, or intramuscular (IM) MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses)
Subjects must have moderately to severely active RA disease as defined by all of the following:
Subjects must have a documented inadequate response to treatment (i.e., TNFi failure) with ≥1 licensed TNFi following at least 12 weeks of therapy with that agent. Inadequate response to treatment is classified as either:
Exclusion Criteria:
Prior use of bDMARDs, within the following windows prior to baseline (bDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):
Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):
Subjects with concurrent acute or chronic viral or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or virus antibody [HCV Ab])
a) subjects who are positive for hepatitis B surface antibodies (anti-HBs), but negative for HBsAg and anti-HBc, will be eligible.
Subjects with:
OR
Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olokizumab 64mg subcutaneous q4w + placebo + Methotrexate Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
Drug: Olokizumab · Drug: Placebo
Olokizumab 64mg subcutaneous q2w + Methotrexate 64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)
Drug: Olokizumab
Placebo q2w subcutaneous + Methotrexate Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group.
Drug: Placebo
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Percentage of Subjects Achieving Low Disease Activity
Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12
Time frame: at Week 12
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).
Time frame: Baseline to Week 12
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12
Time frame: at Week 12
Enrollment was conducted at 123 clinical sites across 11 countries (US,EU, Russian Federation, Asia, Latin America). 718 subjects were screened and 368 subjects were enrolled (randomized) and treated, 318 subjects completed the study. A total of 368 subjects were analyzed for efficacy in the ITT Population and 368 subjects were analyzed for safety in the Safety Population.
| Milestone | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only |
|---|---|---|---|---|---|
| Started | 161 | 138 | 26 | 32 | 11 |
| Completed | 134 | 128 | 25 | 30 | 1 |
| Not completed | 27 | 10 | 1 | 2 | 10 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 23 | 9 | 0 | 2 | 9 |
| Withdrew: Lack of response at week 14 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Subject refused to continue the study | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject was taking prohibited medications and refused to stop. | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing adverse events (low platelet count) with long interruptions of investigational product | 0 | 1 | 0 | 0 | 0 |
The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Arm 1: Olokizumab 64 mg q4w | Arm 2: Olokizumab 64 mg q2w | Arm 3: Placebo q2w |
|---|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 96 | 84 | 28 |
Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12
| Participants | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 3: Placebo q2w |
|---|---|---|---|
| Percentage of Subjects Achieving Low Disease Activity | 47 | 55 | 8 |
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).
| score on a scale | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 3: Placebo q2w |
|---|---|---|---|
| Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.39 ± 0.048 | -0.49 ± 0.056 | -0.32 ± 0.063 |
Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 3: Placebo q2w |
|---|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 52 | 46 | 11 |
Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12
| Participants | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 3: Placebo q2w |
|---|---|---|---|
| Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 5 | 9 | 0 |
Collected over All AEs were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment, up to approximately 44 weeks. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: OKZ 64 mg q4w | 0/160 (0%) | 6/160 (3.8%) | 38/160 (23.8%) |
| Arm 2: OKZ 64 mg q2w | 0/139 (0%) | 12/139 (8.6%) | 38/139 (27.3%) |
| Arm 3: Placebo q2w | 0/69 (0%) | 0/69 (0%) | 16/69 (23.2%) |
| Arm 4: Placebo-OKZ 64 mg q4w | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Arm 5: Placebo-OKZ 64 mg q2w | 0/32 (0%) | 0/32 (0%) | 8/32 (25%) |
| Arm 6: Any OKZ 64 mg q4w | 0/186 (0%) | 6/186 (3.2%) | 40/186 (21.5%) |
| Arm 7: Any OKZ 64 mg q2w | 0/171 (0%) | 12/171 (7%) | 46/171 (26.9%) |
| Total | 0/368 (0%) | 18/368 (4.9%) | 98/368 (26.6%) |
| Event | Arm 1: OKZ 64 mg q4w | Arm 2: OKZ 64 mg q2w | Arm 3: Placebo q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 6: Any OKZ 64 mg q4w | Arm 7: Any OKZ 64 mg q2w | Total |
|---|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 1/160 | 1/139 | 0/69 | 0/26 | 0/32 | 1/186 | 1/171 | 2/368 |
| Pilonidal cystInfections and infestations | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| SepsisInfections and infestations | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Aspartate aminotransferase increasedInvestigations | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Transaminases increasedInvestigations | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| CholecystitisHepatobiliary disorders | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Hip fractureInjury, poisoning and procedural complications | 0/160 | 1/139 | 0/69 | 0/26 | 0/32 | 0/186 | 1/171 | 1/368 |
| Event | Arm 1: OKZ 64 mg q4w | Arm 2: OKZ 64 mg q2w | Arm 3: Placebo q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 6: Any OKZ 64 mg q4w | Arm 7: Any OKZ 64 mg q2w | Total |
|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 13/160 | 10/139 | 0/69 | 0/26 | 1/32 | 13/186 | 11/171 | 24/368 |
| NasopharyngitisInfections and infestations | 7/160 | 9/139 | 1/69 | 0/26 | 1/32 | 7/186 | 10/171 | 18/368 |
| Aspartate aminotransferase increasedInvestigations | 8/160 | 9/139 | 1/69 | 0/26 | 1/32 | 8/186 | 10/171 | 19/368 |
| Latent tuberculosisInfections and infestations | 6/160 | 4/139 | 0/69 | 1/26 | 2/32 | 7/186 | 6/171 | 13/368 |
| DiarrhoeaGastrointestinal disorders | 3/160 | 6/139 | 0/69 | 0/26 | 2/32 | 3/186 | 8/171 | 11/368 |
| AnaemiaBlood and lymphatic system disorders | 1/160 | 1/139 | 4/69 | 0/26 | 2/32 | 1/186 | 3/171 | 8/368 |
| Upper respiratory tract infectionInfections and infestations | 6/160 | 5/139 | 4/69 | 0/26 | 1/32 | 6/186 | 6/171 | 16/368 |
| InfluenzaInfections and infestations | 0/160 | 5/139 | 4/69 | 0/26 | 1/32 | 0/186 | 6/171 | 10/368 |
| Injection site erythemaGeneral disorders | 7/160 | 1/139 | 0/69 | 0/26 | 0/32 | 7/186 | 1/171 | 8/368 |
| HypertensionVascular disorders | 1/160 | 4/139 | 3/69 | 1/26 | 0/32 | 2/186 | 4/171 | 9/368 |
Arm 3 (Placebo) combines all subjects from Arms 4, 5 and 8. Starting at Week 16, subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w. (Efficacy data are presented for Arm 1, Arm 2, and Arm 3.)
| Age, Categorical(Participants) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 132 | 114 | 20 | 27 | 7 | 300 |
| >=65 years | 29 | 24 | 6 | 5 | 4 | 68 |
| Age, Continuous(years) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| Mean | 53.9 ± 11.68 | 53.4 ± 12.68 | 53.5 ± 14.13 | 53.9 ± 11.67 | 48.9 ± 18.28 | 53.5 ± 12.43 |
| Sex: Female, Male(Participants) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| Female | 130 | 122 | 20 | 27 | 8 | 307 |
| Male | 31 | 16 | 6 | 5 | 3 | 61 |
| Race/Ethnicity, Customized(Participants) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| Asian | 3 | 6 | 1 | 1 | 0 | 11 |
| Black of African American | 11 | 11 | 0 | 1 | 0 | 23 |
| White | 139 | 110 | 19 | 24 | 10 | 302 |
| Other/Mixed | 8 | 11 | 6 | 6 | 1 | 32 |
| Region of Enrollment(participants) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| Colombia | 3 | 5 | 2 | 3 | 0 | 13 |
| Argentina | 14 | 11 | 1 | 2 | 0 | 28 |
| South Korea | 1 | 2 | 0 | 1 | 0 | 4 |
| Hungary | 8 | 10 | 2 | 3 | 1 | 24 |
| United States | 63 | 44 | 10 | 8 | 3 | 128 |
| Czechia | 17 | 13 | 2 | 2 | 2 | 36 |
| Brazil | 8 | 11 | 1 | 3 | 1 | 24 |
| Poland | 5 | 5 | 0 | 2 | 1 | 13 |
| Mexico | 27 | 28 | 8 | 8 | 2 | 73 |
| Germany | 3 | 1 | 0 | 0 | 0 | 4 |
| Russia | 12 | 8 | 0 | 0 | 1 | 21 |
| Body Mass Index (BMI),Continuous(kg/m^2) | Arm 1: Olokizumab q4w | Arm 2: Olokizumab q2w | Arm 4: Placebo-OKZ 64 mg q4w | Arm 5: Placebo-OKZ 64 mg q2w | Arm 8: Placebo Only | Total |
|---|---|---|---|---|---|---|
| Mean | 29.218 (17.99 to 56.25) | 28.755 (17.78 to 57.93) | 28.895 (20.74 to 49.93) | 28.467 (17.82 to 37.60) | 26.976 (21.09 to 38.37) | 28.888 (17.78 to 57.93) |
Showing the first 100 of 116 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Sep 2019, 31 months.
Results were first posted in Jul 2021, 1 year 10 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab